Phaseline

Companies › Nature Cell

Nature Cell: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JointStem
Autologous adipose tissue-derived mesenchymal stem cells (AdMSC)
–Phase 2Osteoarthritis, KneeAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04368806JointStemPhase 2Osteoarthritis, KneeImmunologyAug 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cellcolabs Clinical SPV EHL Bio Throne Biotechnologies Xentria Restem

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.